Role of baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment
| Autor: | Tugba Akin Telli, Salih Ozguven, Ozkan Alan, Nuh Filizoglu, Mehmet Akif Ozturk, Nisanur Sariyar, Selver Isik, Rukiye Arikan, Nazim Can Demircan, Tugba Basoglu, Ilknur Alsan Cetin, Tunc Ones, Ozlem Ercelep, Faysal Dane, Perran Fulden Yumuk |
|---|---|
| Přispěvatelé: | AKIN TELLİ T., ÖZGÜVEN S., Alan O., Filizoglu N., ÖZTÜRK M. S. , Sariyar N., Isik S., Arikan R., DEMİRCAN N. C. , BAŞOĞLU TÜYLÜ T., et al. |
| Rok vydání: | 2022 |
| Předmět: |
Internal Medicine Sciences
Nükleer Tıp Klinik Tıp Radiological and Ultrasound Technology Dahili Tıp Bilimleri General Medicine CLINICAL MEDICINE Sağlık Bilimleri Clinical Medicine (MED) Tıp Radyoloji ve Ultrason Teknolojisi Nuclear medicine Health Sciences Medicine Radyoloji Nükleer Tıp ve Görüntüleme Klinik Tıp (MED) Radiology Nuclear Medicine and imaging RADYOLOJİ NÜKLEER TIP ve MEDİKAL GÖRÜNTÜLEME Ga-PSMA PET/CT · Metastatic castration-resistant prostate cancer · Survival · Whole-body volumetric parameters RADIOLOGY NUCLEAR MEDICINE & MEDICAL IMAGING |
| Zdroj: | Annals of Nuclear Medicine. 36:964-975 |
| ISSN: | 1864-6433 0914-7187 |
| Popis: | Objective We aimed to evaluate whether baseline Ga-68-PSMA PET/CT-derived whole-body volumetric parameters could be used as predictive biomarkers for survival in metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line treatment. Materials and methods This retrospective study included 54 mCRPC patients, who underwent baseline Ga-68-PSMA PET/CT imaging within 1 month before starting first-line treatment. Pre-treatment prostate-specific antigen (PSA) levels and treatments were recorded. SUVmax, SUVmean, whole-body PSMA-derived tumor volume (wbPSMA-TV), and whole-body total lesion PSMA (wbTL-PSMA) were calculated for all patients. PSA response was defined as a decline of >= 50% from pre-treatment value at 12 weeks. Overall survival (OS) was measured from the start of the first-line treatment for mCRPC. Results Docetaxel and abiraterone/enzalutamide were administered to 32 and 22 patients in the first-line setting, respectively. wbPSMA-TV (rho = 0.582, p = 0.004) and wbTL-PSMA (rho = 0.564, p = 0.007) showed moderate positive correlations with PSA levels. Older age (p = 0.02), higher wbPSMA-TV (p = 0.007), higher PSA (p = 0.01), higher number of bone metastases (p = 0.02), and lack of PSA response (p = 0.03) were significantly associated with an increased risk of mortality. Multivariate analysis determined wbPSMA-TV (HR: 1.003, 95% CI 1.001-1.004, p = 0.001) and PSA response (HR: 2.241, 95% CI 1.189-4.222, p = 0.01) as independent predictors of OS. Conclusion The wbPSMA-TV may be a useful tool to reflect tumor burden and predict survival outcomes in patients with mCRPC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink